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The long-term clinical outcome of pediatric intracranial epepdymoma is poor with a high rate of recurrence. One of
the main reasons for this poor outcome is the tumor’s inherent resistance to chemotherapy. Signal transducer and
activator of transcription 3 (STAT3) is overactive in many human cancers, and inhibition of STAT3 signaling is an
emerging area of interest in oncology. In this study, the possibility of STAT3 inhibition as a treatment was
investigated in pediatric intracranial ependymoma tissues and cell lines. STAT3 activation status was checked in
ependymoma tissues. The responses to conventional chemotherapeutic agents and a STAT3 inhibitor WP1066 in
primarily cultured ependymoma cells were measured by cell viability assay. Apoptosis assays were conducted to
reveal the cytotoxic mechanism of applied agents. Knockdown of STAT3 was tried to confirm the effects of STAT3
inhibition in ependymoma cells. High levels of phospho-STAT3 (p-STAT3) expression were observed in
ependymoma tissue, especially in the anaplastic histology group. There was no cytotoxic effect of cisplatin,
ifosfamide, and etoposide. Both brain tumor-initiating cells (BTICs) and bulk tumor cells (BCs) showed
considerably decreased viability after WP1066 treatment. However, BTICs had fewer responses than BCs. No
additive or synergistic effect was observed for combination therapy of WP1066 and cisplatin. WP1066 effectively
abrogated p-STAT3 expression. An increased apoptosis and decreased Survivin expression were observed after
WP1066 treatment. Knockdown of STAT3 also decreased cell survival, supporting the critical role of STAT3 in
sustaining ependymoma cells. In this study, we observed a cytotoxic effect of STAT3 inhibitor on ependymoma
BTICs and BCs. There is urgent need to develop new therapeutic agents for pediatric ependymoma. STAT3
inhibitors may be a new group of drugs for clinical application.
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Ependymoma is an intra-axial brain tumor that predominantly
develops in young children. In the histological grading system of brain
tumors proposed by the World Health Organization (WHO),
ependymomas correspond to either grade 2 (classic) or grade 3
(anaplastic variant) [1]. However, the prognosis of ependymoma is
dire despite its modest histological grade. Long-term survival rates of
pediatric ependymoma patients range from 50 to 70% [2–5]. In a
recently published analysis of our patients’ outcome, we observed a
high rate of tumor recurrence (73% of patients). The five-year overall
survival rate was only 71% [6]. The poor treatment outcome of
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of current treatment protocols.
Current treatment protocols for intracranial ependymoma consist
of a maximal surgical resection followed by local radiation therapy
(RT). Ependymoma is intrinsically resistant to chemotherapy and
currently no reliable and uniform chemotherapy regimen exists for
this tumor. RT has a moderate effect on tumor control of intracranial
ependymomas and most treatment protocols advocate early postop-
erative RT. However, the average age of ependymoma patients is
younger than that of medulloblastoma. In our previous study, 42% of
patients were under the age of three at diagnosis—the conventional
age threshold to allow safe delivery of high-dose radiation to
developing brains [6]. Recently, clinicians in the St. Jude Children’s
Research Hospital reported that early application of conformal RT,
even to patients under one year, could raise the local control rate of
intracranial ependymoma to over 80% [7]. This should be considered
as a true improvement, but RT for such a young-age group needs to
be more sophisticated in application. In this context, development of
a new therapeutic agent can provide a robust means to prevent
surgical complications, to postpone RT until brain maturation, and to
enhance the survival of the children.
Signal transducer and activator of transcription 3 (STAT3) is a
crucial intracellular signal transducer that, once activated by various
growth factors and cytokines, binds to DNA and guides specific gene
expression [8]. STAT3 protein expression has been known to be
elevated in many kinds of human cancers [9]. Furthermore, in some
cancers such as colorectal, ovarian, and renal cell carcinomas, high
STAT3 expression was associated with poor prognosis of patients
[10–12]. Especially, STAT3 may play a role in augmenting
chemo-resistance in many types of human cancers [13–15]. Many
kinds of STAT3 inhibitors have been developed [8,9]. WP1066 is a
potent inhibitor of JAK2 and its downstream STAT3 pathways.
WP1066 showed marked suppressive activities on many type of
cancer cells including leukemia, renal cell carcinoma, and glioblas-
toma, both in vitro and in vivo [16–18]. Therefore, the STAT3
inhibitor may be a potentially promising therapeutic agent for
intrinsically chemo-resistant tumors like intracranial ependymoma.
During the last decade, tumor-initiating cells have been found in
many solid cancers including brain tumors [19]. These tumor-initiat-
ing cells have demonstrated stem cell–like characteristics in gene
expression, sphere-formation in specialized culture media, and serial
tumor formation after transplantation into immune-deficient mice.
Tumor-initiating cells may have an important role in chemo-
resistance, tumor dormancy, and metastasis [20,21]. Interestingly, in
colon cancer cells, ALDH+/CD133+ tumor-initiating cells showed
higher STAT3 activation levels and these cells were sensitive to
STAT3 inhibition [22]. Brain tumor–initiating cells (BTICs) are also
found in ependymoma [23]. In this study, the potential of a STAT3
inhibitor, WP1066, to suppress ependymoma cell growth and to
overcome chemo-resistance was evaluated in the context of BTICs
and bulk tumor cells (BCs) to test the therapeutic potentials of
STAT3 inhibitors for pediatric ependymoma.
Materials and Methods
Human Brain Tissues
Fresh human brain tumor specimens were collected from patients
undergoing respective surgery at the Seoul National University
Children’s Hospital. Eligible patients or their parents providedwritten informed consent to provide the tumor tissues. The
institutional review board of the Seoul National University Hospital
approved the tissue banking and this study protocol. None of the
patients received neoadjuvant therapies. Non-tumor brain tissues
were obtained from patients receiving surgery for pharmacologically
intractable epilepsy. Tissues used for experiments are as follows:
epilepsy (N = 5), ependymoma (WHO grade 2; N = 6), and
anaplastic ependymoma (WHO grade 3; N = 6). Tissue selection was
determined by tissue availability and performed by a person blinded
to the treatment outcome of the patients.
Reagents
WP1066, a STAT3 inhibitor was purchased from Skelleckchem
(Houston, TX). Chemotherapeutic agents cisplatin, ifosfamide, and
etoposide were obtained from Sigma-Aldrich (St. Louis, MO). All the
agents were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich).
Stock solutions were made at a concentration of 50 mM in DMSO
and stored at −20°C.
Primary Cell Culture
Fresh tumor tissues were mechanically chopped in Dulbecco’s
phosphate-buffered saline (Invitrogen, Grand Island, NY) without
calcium and magnesium before enzymatic digestion. Within 6 h after
resection, tissues were washed and enzymatically dissociated into
single cells and filtered through a 40 μm filter. Red blood cells were
removed. Live cells were seeded at a standard density of 2 × 105 cells/
cm2 Primary tumor cell cultures were maintained in Neurobasal
Medium (Invitrogen) containing 2 mM L-glutamine, N2 supple-
ment, B27 supplement, and 20 ng/ml of human recombinant
epidermal growth factor (Chemicon, Temecula, CA) and a basic
fibroblast growth factor (Chemicon). To generate tumor spheres, the
cells were seeded at a standard density of 2 × 105 cells/cm2 at each
passage. Spheres were maintained and subcultures were performed
accordingly. All primarily cultured cells were used for in vitro
experiments in less than four cell passages. For BC culture, tumor cells
were transferred to Dulbecco's Modified Eagle's Medium (Invitro-
gen) supplemented with 10% fetal bovine serum (Invitrogen) and
penicillin–streptomycin (×1 final concentration; Invitrogen). All cells
were maintained at 37°C with 5% CO2 in a humidified atmosphere.
Neural stem cells (NSCs) were cultured in the same media condition.
Because we used only early-passage (b4) cells for all in vitro
experiments, five different primary ependymoma cell lines were used
(designated as SNU-EP1, SNU-EP2, SNU-EP3, SNU-EP4, and
SNU-EP5, respectively). SNU-EP1, SNU-EP2, SNU-EP3,
SNU-EP4 cells originated from grade 3 anaplastic ependymomas
(patient age 16 years, 3 years, 5 years, and 25 months, respectively).
SNU-EP5 cells were from WHO grade 2 ependymoma (patient age
25 months). Neural stem cells were primarily cultured from the
human neocortex obtained during epilepsy surgery. A human
astrocyte cell line (Life Technologies, Carlsbad, CA) further
immortalized with SV40 and hTERT was used (courtesy of Professor
Jong Bae Park at National Cancer Center, Korea).
In Vitro Sphere Formation Assay
For tumor-sphere formation assay, dissociated cells (1 × 103 cells,
N = 3) were plated onto poly-L lysine-coated eight-well plates (Nunc,
Rochester, NY) in serum-free Neurobasal medium with B27
supplement (Invitrogen) for 2 to 7 days. The number of tumor-
spheres with a diameter N40 μm were counted with an inverted
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were performed in triplicate.
Characterization of Spheroid Cells
For characterization of tumor-spheres, spheroid cells were fixed in
2% paraformaldehyde. Immunofluorescence was performed using the
following antibodies: Nestin (Chemicon; 1:200) or Musashi
(Neuromics, Bloomington, MN; 1:100). The secondary antibodies
Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor
594-conjugated goat anti-rabbit (Invitrogen; 1:200) were used. The
cells were mounted with an anti-fading solution containing
4′-6-diamidino-2-phenylindole (Vector Laboratories, Burlingame,
CA). Fluorescent images were obtained using a confocal microscope
(Zeiss, Oberkochen, Germany). All experiments were conducted
in triplicate.
Cell viability assay
The cytotoxic effect of WP1066, cisplatin, ifosfamide, or etoposide
was determined using the colorimetric cell counting kit-8 (Dojindo
Molecular Technologies, Gaithersburg, MD) that shows good
correlation with the [3H]-thymidine incorporation assay. Dissociated
spheres were plated in 96-well plates in 100 μl of serum free media
supplemented with growth factors or Dulbecco's Modified Eagle's
Medium media supplemented with fetal bovine serum, at a density of
5 × 103 cells per well. F3 cells used as a control cell for detecting
cytotoxic effect to normal stem cells. After exposure to drugs (at
concentrations from 0 μM to 50 μM) for 48 hours, the colorimetric
cell counting kit-8 reagent was added to each well. The absorbance of
the samples against a background control was measured using a
Microplate Reader (Molecular Devices, Sunnyvale, CA) at a
wavelength of 450 nm. The viability of non-treated cells was
regarded as 100%. IC50 values represent the drug concentrations
required to inhibit 50% of cell viability and were calculated with a
linear regression line of the plot of percentage inhibition.
Terminal Deoxynucleotidyl Transferase dUTP Nick end
Labeling (TUNEL) Assay
Cells were grown on glass coverslips. After treatment withWP1066
for 48 h, TUNEL staining was performed using Click-iT TUNEL
Alexa Fluor 594, as recommended by the supplier (Invitrogen).
Cells were counterstained with Hoechst dye for the nuclei and
fluorescent images were obtained using a confocal microscope (Zeiss).
The results are from three independent experiments. The apoptotic
cell rate was determined according to the formula: (number of
apoptotic cell with red staining/total number of cells with 4′-6-
diamidino-2-phenylindole staining) × 100%.
Annexin V Assay
In order to evaluate the stages of apoptosis, cells were stained with
the Annexin V-FITC Apoptosis Detection kit (BD Bioscience, San
Jose, CA) and counterstained with propidium iodide (PI; BD
Bioscience) after a 24-hour WP1066 treatment. Fluorescent
intensities were determined by a FACSCalibur flow-cytometer
(Becton Dickinson, San Jose, CA). The experiment was repeated
three times.
Western Blotting
Total proteins were extracted from brain tissues and cells using
protein lysis buffer (Cell Signaling Technologies, Danvers, MA).
Equal amounts of protein (30 μg) were mixed with NuPAGE samplebuffer (Invitrogen), boiled for 10 minutes at 70°C. Then the samples
were separated by sodium NuPAGE 4% to 12% Bis-Tris gel
(Invitrogen) and transferred to a nitrocellulose i-blot gel transfer stack
(Invitrogen) using i-blot system (Invitrogen). After the membrane
had been blocked with Tris-buffered saline containing 5% non-fat
dry milk, the membranes were treated with anti-STAT3, anti–
phospho-STAT3 (p-STAT3; Cell signaling, 1:1,000), anti–cleaved
caspase-3 (Cell signaling, 1:1,000), anti–BCL-XL (Cell signaling,
1:1,000), anti-BCL2 (Abcam, Cambridge, MA, 1:1,000), anti-
Interleukin 6 (IL-6; Abcam, 1:1,000), anti-IL6R (Thermo
Fisher Scientific, Rockford, IL, USA, 1:1,000), anti-ABCC4 (Cell
signaling, 1:1,000), anti-Survivin (Abcam, 1:5,000), and anti–β-actin
(Sigma-Aldrich, 1:5,000). The blots were developed with enhanced
chemiluminescence reagent (Invitrogen) and were exposed to film.
The blot densities of the proteins were normalized to the levels of
internal β-actin expression and were represented as the relative
intensity values.
Knockdown experiment with STAT3 siRNAs
For knockdown analysis of STAT3, siRNAs were used. Negative
control siRNA (NC-siRNA, Cat. #SN-1002), STAT3-siRNA1 (Cat.
#1145660) and STATt3-siRNA2 (Cat. #1145658) were purchased
from Bioneer (Daejeon, Korea); 50 nM of NC-siRNA, STAT3-
siRNA1, or STAT3-siRNA2 was transfected into the cells using
RNAiMax Lipofectamine (Invitrogen) following the manufacturer’s
instructions. Knockdown efficiency and specificity with siRNA was
confirmed by Western blot.
Statistical Analysis
Unpaired t test was applied to compare continuous variables
between two groups, A Kruskal-Wallis test was used for comparison
of continuous variables in three groups. IBM SPSS version 19.0
software (IBM, Armonk, NY) was used for statistical analyses.
Results
STAT3 Activation in Ependymoma Tissues
The status of STAT3 activation was assessed using western blotting
in fresh-frozen tissues of ependymoma (WHO grade 2) and anaplastic
ependymoma (WHO grade 3). Brain tissues from focal cortical
dysplasia patients were used as controls. The STAT3 expression was
highly elevated in tumor tissues compared with controls (Figure 1A).
Tumor tissues also showed high level of STAT3 activation with thick
bands for p-STAT3. Three of six cases of ependymoma showed high
p-STAT3 expression and five of six cases of anaplastic ependymoma
revealed high p-STAT3 expression. In semi-quantitative measuring,
there was a marginal difference in STAT3 band intensities among the
three categories (P = .0546; Kruskal-Wallis test), but a significant
difference was noted in p-STAT3 band intensity (P = .0298;
Kruskall-Wallis test; Figure 1B). Immunohistochemistry of paraffin-
embedded tissue revealed nuclear labeling of p-STAT3 in tumor cells and
confirmed increased p-STAT3 expression in anaplastic ependymoma
(Figure 1D).
Culture of BTICs and BCs
Four fresh tumor tissues were chopped, dissociated, and cultured
into two different conditions. One is a culture method optimized for
BTICs and the other is a serum-added condition for BCs. BTICs
formed multiple characteristic spheroids, whereas BCs showed an
elongated morphology (Figure 2A). In immunofluorescence, BTICs
CB
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p-STAT3
STAT3
β-actin
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FCD EPD AEPDD
10
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Figure 1. STAT3 expression in ependymoma tissues. (A) Western blot revealed abundant expression of STAT3 and p-STAT3 in WHO
grade 2 ependymoma (EPD) and WHO grade 3 anaplastic ependymoma (AEPD) compared to brain tissues (Brain). (B and C) In
semi-quantitative measurement, the band intensity of STAT3 was marginally different in the three categories (P= .0546), but there was a
significant difference of p-STAT3 expression among the groups (P = .0298). (D) Immunohistochemistry for p-STAT3 showed increasing
proportions of p-STAT3-positive tumor cells according to the histopathological grade. Horizontal bars represent 100 μm. *P b .05.
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Musashi (Figure 2B). These markers were not expressed in BCs (data
not shown).
Sensitivity of EpendymomaCells toVariousChemotherapeutic Agents
To assess the cytotoxic effect of chemotherapeutic agents currently
used for intracranial ependymomas, cell viability assay was conducted
for SNU-EP1 cells after treatment of cisplatin, ifosfamide, etoposide,
or WP1066 in serial concentrations. Drugs were delivered to either
BTICs or BCs of SNU-EP1 cells, respectively. There was virtually no
cytotoxic effect of cisplatin and ifosfamide (Figure 3, A and B).
Etoposide showed a modest decrease of cell viability (Figure 3C). In
contrast, WP1066 showed smaller IC50 value for BCs than all
chemotherapeutic agents tested above. The IC50 value of WP1066 for
BTICs was similar to that of etoposide (Figure 3D). The IC50 values
of drugs for SNU-EP1 cells were summarized in Table 1.
WP1066 Treatment to EpendymomaCells, NSCs, and Astrocytes
For four other primary ependymoma cell lines (SNU-EP2,
SNU-EP3, SNU-EP4, and SNU-EP5 cells), treatment of WP1066
resulted in cytotoxicity to both BTICs and BCs (Figure 4). The IC50
values for the cell lines are summarized in Table 2. Inhibition of BCswere more effective that suppression of BTICs in all ependymoma cell
lines except for in SNU-EP3 cells. Interestingly, BTICs of SNU-EP3
cells escaped the suppressive effect of WP1066 at higher concentra-
tions. It is noteworthy that primary NSCs and astrocytes exhibited
higher IC50 values than ependymoma cell lines (Table 2).
Combination Treatment of WP1066 and Conventional
Chemotherapeutic Agents
Cell viability was assessed after various combinations ofWP1066 and
conventional chemotherapeutic agents in two ependymoma cell lines
(SNU-EP1 and SNU-EP2). As shown in Table 1, cisplatin and
ifosfamide alone showed no cytotoxic effects and etoposide exhibited
modest cytotoxic effects on SNU-EP1 cells. Combination of
conventional agents with WP1066 yielded no additive or synergistic
effect for all cell lines compared with the response to WP1066 alone
(Figure 5). Indeed, cytotoxic effects ofWP1066 seemed to be hampered
by adding conventional agents. There were nomeaningful differences in
the response patterns between day 2 and day 3 after drug treatment.
Increased Apoptosis After WP1066 Treatment
TUNEL and Annexin V assays were performed for SNU-EP1 and
SNU-EP2 cells to verify whether WP1066 induces apoptosis in
SNU-EP2 
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Figure 2. Distinct morphological divergence of ependymoma cells in two different culture conditions. A. Upper row is BCs cultured in
serum-containing media and the lower row is BTICs cultured in serum-free media (original magnification, ×200). (B) Expression of stem
cell markers in ependymoma BTICs. Immunofluorescence images showed intense expression of Nestin and Musashi in the tumor
spheres of ependymoma BTICs.
380 Phi et al. Translational Oncology Vol. 8, No. 5, 2015ependymoma cells. In TUNEL assay, apoptotic cells increased
significantly at 48 hours from WP1066 treatment (Figure 6). In
Annexin V assay, augmentation of early apoptosis was more
prominent than increase of late apoptosis after a 24 hours WP1066
treatment (Figure 7). In SNU-EP1 cells, there was significant increaseA
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Table 1. Comparison of the half maximal inhibitory concentration (IC50) values for drugs in
ependymoma cells (SNU-EP1)
Drugs BC BTIC
Cisplatin 95.5 ± 19.9 213.6 ± 149.6
Ifosfamide 152.1 ± 47.3 113.0 ± 12.3
Etopside 49.7 ± 2.9 49.4 ± 1.5
WP1066 39.4 ± 2.2 55.9 ± 1.9
BC, BTIC, the IC50 value, relative to untreated control. IC50 ± SD (μM).
Table 2. Comparison of the half maximal inhibitory concentration (IC50) for WP1066 in various
tumor and normal cell lines
Cells BC BTIC
SNU-EP2 3.1 ± 0.5 12.3 ± 1.3
SNU-EP3 20.4 ± 1.9 5.6 ± 0.8
SNU-EP4 21.5 ± 0.9 104.5 ± 5.1
SNU-EP5 1.3 ± 0.1 8.9 ± 5.2
NSC 43.1 ± 2.1*
Astrocyte 26.9 ± 2.0*
BC, BTIC, NSC. The IC50 value, relative to untreated control. IC50 ± SD (μM).
*NSCs were sphere-forming cells and astrocytes were adherent cells.
Translational Oncology Vol. 8, No. 5, 2015 Phi et al. 381Expression of Apoptosis-Related Proteins AfterWP1066Treatment
We observed the expression of cleaved caspase-3 and anti-apoptotic
factors, Bcl-xl and Bcl-2, after WP1066 treatment in SNU-EP1 and
SNU-EP2 cells. At 72 hours after WP1066 treatment, p-STAT3
expression was nadir in both cell lines. Cleaved caspase-3 expression
was paradoxically decreased, indicating that a caspase-independent
mechanism may be working in the apoptosis of ependymoma cells
after STAT3 inhibition. The expression of anti-apoptotic proteins of
Bcl-2 family, Bcl-xl and Bcl-2 was assessed. The level of Bcl-xl was not
changed with WP1066 treatment. Instead, there was a decrease of0
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by WP1066 treatment to some degree, but they were more resistant
IC50 value than immortalized astrocyte cell line.Bcl-2 expression in both cell lines. However, the decrease of Bcl-2
expression was observed 72 hours after WP1066 treatment
(Figure 8A). As we observed increase of apoptosis at 24 to 48 hours
from WP1066 treatment (Figures 6 and 7), it is unlikely that the
delayed decrease of Bcl-2 was the main factor of apoptosis
augmentation. We next checked the expression of Survivin, a
member of other anti-apoptotic protein family. The levels of Survivin0
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Figure 5. Combination treatment of WP1066 and conventional chemotherapeutic agents. Cell viability was assessed after various
combinations of WP1066 and conventional chemotherapeutic agents in two ependymoma cell lines (SNU-EP1 and SNU-EP2). Cell
viability was assessed in day 2 (d2) and day 3 (d3) for each cell line. There was virtually no additive or synergistic effect of drug
combination compared with the response to WP1066 alone. Paradoxically, the cytotoxic effect of WP1066 was decreased by the
combination treatment with conventional chemotherapeutics. Horizontal bars (grey color) represent 50% cell viability.
382 Phi et al. Translational Oncology Vol. 8, No. 5, 2015expression were decreased at 24 h after WP1066 treatment in two cell
lines (SNU-EP1 and SNU-EP2 cells).
Suppression of Ependymoma Cell Viability With STAT3
Knockdown
To verify the important role of STAT3 suppression by WP1066 in
ependymoma cells (SNU-EP1 and SNU-EP2 cells), we tried STAT3
knockdown with specific siRNAs (STAT3-siRNA1 and STAT3-
siRNA2). A decrease of STAT3 expression and further suppression of
p-STAT3 expression were confirmed by western blot with both
STAT3-siRNA1 and STAT3-siRNA2 (Figure 9A). A decrease of
Survivin expression was also observed with STAT3 knockdown in
SNU-EP2 cells. After knockdown of STAT3, the cell viability was
significantly decreased in both cell lines (Figure 9B). These results
further demonstrated the critical role of STAT3 in maintaining
ependymoma cells.
Discussion
STAT3 is an important cellular signal transducer interconnecting
many receptors, signaling pathways, and target genes. In vitro studies
showed that activation of STAT3 pathway leads to enhanced cell
survival, cell cycle progression, and cellular migration, all of which are
cardinal features of malignancy. Indeed, many human cancers showed
overexpression of STAT3 and activation of its signaling that has
prognostic correlation in many instances [10,12]. Therefore,
suppression of the activated STAT3 pathway has been a topic of
investigation for many types of cancer. Inhibition of STAT3 ispossible by administration of specific siRNA, decoy oligonucleotide,
or synthetic or natural inhibitors [9,24]. There are many kinds of
STAT3 inhibitors and WP1066 has been known as a potent inhibitor
of STAT3 pathway [16]. STAT3 is constitutively activated in
malignant glioma and WP1066 have shown growth-suppressing
ability in U87-MR and U373-MG cells in vitro and in vivo [18]. The
cellular effects of STAT3 pathway inhibition are diverse, but the
induction of apoptosis is regarded as the main consequence [16].
Therefore, STAT3 inhibitors can acts as a cytotoxic agent. Silencing
of STAT3 resulted in reduction of glioma cell infiltration into the
mouse brain, thereby prolonging the survival of the animal model
[25]. This finding presents another promising role of STAT3
inhibitors as an anti-invasive agent for malignant brain tumors.
In this study, a STAT3 inhibitor, WP1066 treatment led to robust
suppression of ependymoma cell growth. Conventional chemother-
apeutic agents (cisplatin, ifosfamide, and etoposide) showed
insufficient cytotoxic effects to ependymoma cells in vitro. It has
been postulated that STAT3 signaling is deeply involved in the
acquisition of chemo-resistance of tumor cells [26,27]. In gastric
cancer cells, it was shown that treatment of STAT3 siRNA increased
sensitivity to cisplatin in drug-resistant cell populations [14].
Monoclonal antibody to IL-6, siltuximab, increased the cytotoxicity
of paclitaxel in drug-resistant ovarian carcinoma cell lines by
inhibiting the STAT3 signaling [28].
However, we observed no synergistic effect of combined treatment
of WP1066 and chemotherapeutic agents. Limited efficacy to a
certain group of patients and the emergence of resistance in initially
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90.6 ± 4.30% in WP1066-treated cells (P = .0004; unpaired t test). **P b .01, ***P b .001.
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application of new molecular-targeted agents. At present, we may
have to proceed on trying a single STAT3 inhibitor or to search for an
optimal combination of drugs for ependymoma to maximize the
effect of STAT3 inhibitors.
We demonstrated that anaplastic ependymoma had higher
p-STAT3 expression than grade 2 ependymoma. However, it is not
conclusive whether WP1066 is more effective in suppressing the
viability of anaplastic ependymoma cells, because only one grade 2
ependymoma cell line was used for this study and the cells
(SNU-EP5) exhibited low IC50 values to WP1066.
The last decade witnessed the emerging concept of cancer stem
cells in various solid tumors [21]. The cancer stem cell concept has
been criticized mainly for the lack of out-and-out definitions and
criteria, and for brain tumors, BTIC may be more appropriate term.
BTICs are thought to be dormant in nature and more resistant to
chemotherapy than BCs [20]. Our results showed that BTICs of
ependymoma were more resistant to WP1066 in four out of the five
ependymoma cell lines tested. Only one cell line (SNU-EP3) showed
more effective suppression of BTICs than BCs by WP1066, but
BTICs escaped the suppressive effect at high concentrations.
Nonetheless, WP1066 showed sufficient cytotoxicity to suppress
ependymoma BTICs, considering the inefficiency of conventional
chemotherapeutics on ependymoma cells.
The viability of human NSC and astrocyte cell lines were also
affected by WP1066 treatment, raising some concerns about clinical
application of STAT3 inhibitors. However, their IC50 values were
higher than those of BCs of ependymoma cell lines. Furthermore,NSCs were more resistant to WP1066 than astrocytes. The astrocytes
used in this study had been artificially immortalized after primary
culture, while the NSCs were primarily cultured early-passage cells.
Immortalization is a hallmark phenotype of cancer and immortalized
cells could be more vulnerable to STAT3 inhibition. In this regards,
naïve neurons and glial cells might be protected when STAT3
inhibitors were administrated.
Previous studies suggested that STAT3 inhibitors including
WP1066 augment apoptosis of tumor cells especially through
suppression of anti-apoptotic factors, such as survivin or Bcl-xl [28].
We also observed a dramatic increase of apoptosis after WP1066
treatment in ependymoma cell lines. Bcl-2 and Bcl-xl are anti-apoptotic
proteins that belong to Bcl-2 family. Decrease of Bcl-2 expression was
observed, but it was evident at 72 h after WP1066 treatment, whereas
robust apoptosis was observed in TUNEL staining and Annexin V assay
within 24 to 48 hours. Survivin is a member of other anti-apoptotic
protein family. A decrease of Survivin was observed at 24 h after
WP1066 treatment, making it a candidate mechanism of WP1066
treatment in ependymoma cells.
The central role of STAT3 in maintaining ependymoma cell
survival was further confirmed by knockdown experiments with
specific STAT3-siRNAs. Knockdown of STAT3 yielded cytotoxic
effects on ependymoma cells, supporting the critical role of STAT3 in
these tumor cells and the therapeutic potentials of STAT3-targeting
strategy in ependymomas.
At present, several human clinical trials are ongoing that target
refractory solid tumors with novel STAT3 inhibitors (OPB-31121
and OPB-51602) and chronic lymphocytic leukemia with an
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Figure 7. Annexin V assays in two ependymoma cell lines after WP1066 treatment. Increase of apoptotic cell proportion was more
prominent in early apoptosis. In SNU-EP1 cells, the proportions of early apoptotic cells were 0.96 ± 0.27% in control cells and 7.7 ±
2.66% in WP1066-treated cells (P = .0468; unpaired t test). There was no significant difference in the proportions of late apoptotic cells
(9.87 ± 0.80% in control cells and 13.1 ± 1.65% inWP1066-treated cells; P= .0590; unpaired t test). In SNU-EP2 cells, the proportions of
early apoptotic cells were 2.55 ± 0.45% in control cells and 18.8 ± 1.56% in WP1066-treated cells (P = .0016; unpaired t test). The
proportions of late apoptotic cells were 4.30 ± 0.32% in control cells and 12.6 ± 0.24% in WP1066-treated cells (P b .0001; unpaired
t test). *P b .05, **P b .01.
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actions [29]. In our study, we observed cytotoxic effect of STAT3
inhibitor to ependymoma BTICs and BCs. We have urgent needs top-STAT3
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Figure 9. STAT3 knockdown and cell viability. (A) Decrease of STAT3 expression was observed with STAT3-siRNA treatment in SNU-EP1
and SNU-EP2 cells. Expression of p-STAT3 was further suppressed. A decrease of Survivin expression was also observed in SNU-EP2
cells which exhibited strong suppression of Survivin expression after WP1066 treatment. (B) Cell viability was significantly decreased in
SNU-EP1 cells after treatment of two different STAT3-siRNAs (control vs siRNA1: 100.0 ± 2.5% vs 79.3 ± 12.3%, P= 0.0081; control vs.
siRNA2: 67.9 ± 5.3%, P b .0001; unpaired t test). Significant decrease of cell viability was also observed in SNU-EP2 cells (control vs
siRNA1: 100.0 ± 9.6% vs 72.7 ± 9.3%, P= .0032; control vs. siRNA2: 67.7 ± 1.4%, P= 0.0003). NC-siRNA = negative control siRNA,
*P b .05, **P b .01, ***P b .001.
Translational Oncology Vol. 8, No. 5, 2015 Phi et al. 385Conclusions
In vitro studies indicated that a STAT3 inhibitor, WP1066 has
cytotoxic effect to ependymoma cells. Considering the high resistance
of ependymoma cells to various chemotherapeutic agents, this is a
promising result. STAT3 inhibitors may be a new group of drugs for
intracranial ependymomas.
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